(APYX) Apyx Medical - Ratings and Ratios

Apyx Medical Corporation, a leader in energy-based medical technology, specializes in the development and manufacturing of advanced surgical devices. The company operates through two primary segments: Advanced Energy, which focuses on its proprietary Helium Plasma Technology, and Original Equipment Manufacturing (OEM), which provides custom solutions for medical device companies. Its flagship product, the Helium Plasma Generator, delivers precise RF energy and helium plasma for cutting, coagulating, and ablating soft tissue in both open and minimally invasive surgical procedures. These products are marketed under the Renuvion brand in the cosmetic surgery market and the J-Plasma brand in the hospital surgical market. Additionally, the company designs and manufactures hand pieces for laparoscopic and open procedures, as well as OEM generators and accessories. Formerly known as Bovie Medical Corporation, Apyx Medical Corporation rebranded in January 2019 to reflect its strategic shift toward innovative energy-based technologies. Founded in 1982, the company is headquartered in Clearwater, Florida.

Over the next three months, Apyx Medical Corporation is expected to face headwinds as its stock price currently trades below its 20-day, 50-day, and 200-day moving averages, indicating bearish momentum. The average true range (ATR) of 0.12 suggests limited volatility, which may constrain significant price movement in either direction. Fundamental analysis highlights a market cap of $44.80M, with a price-to-sales (P/S) ratio of 0.92, which may indicate undervaluation relative to its revenue. However, the price-to-book (P/B) ratio of 4.52 signals a premium relative to its book value. With no P/E ratio available due to lack of earnings, investors may remain cautious. The companys focus on minimally invasive surgical solutions and its OEM partnerships could drive long-term growth, but near-term challenges may persist.